Global Gel Documentation Systems Market 2017-2021
About Gel Documentation Systems
Gel documentation systems or gel imaging systems could be defined as a package of instruments used to record and measure nucleic acid and protein in various types of media such as cellulose, acrylamide, and agarose. These systems come in a variety of configurations depending on the desired application and sample type. A typical gel documentation system consists of a camera with lenses of variable detection power, imaging filters, overhead illuminator, passage of light, which illuminates the gel placed on an adjustable stage and an additional transilluminator which enables collection of light. Through the use of chemiluminescence and fluorescence, gel documentation systems are deployed for various applications is hospitals, diagnostic centers, and research institutions.
Technavio’s analysts forecast the global gel documentation systems market to grow at a CAGR of 6.93% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global gel documentation systems market for 2017-2021. To calculate the market size, the report considers the revenue generated from retail sales of gel documentation systems to the various end-users discussed in this report.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Gel Documentation Systems Market 2017-2021
Technavio recognizes the following companies as the key players in the global gel documentation systems market: Bio-Rad, GE Healthcare, and Thermo Fisher Scientific.
Other Prominent Vendors in the market are: Analytik Jena, Cleaver Scientific, Corning, eikonix, Gel Company, Syngene, TBG Diagnostics, and VWR International.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is rising costs of clinical trials. Clinical trial management has changed significantly over the years, and hence there has been a growing concern of the rising costs of clinical trials. Drugs undergo a difficult and slow process during clinical trials. The initial difficulty is that of patient enrolment, which is followed by making sure patients continue the trial and not drop out of the research study.”
According to the report, one of the major drivers for this market is increase in use of molecular biology techniques in clinical practice. Molecular biological methods which were initially used for detection of microorganisms have now become an important aspect of diagnostic microbiology and hence part of routine specimen processing. PCR techniques have led the way by allowing rapid detection of microorganisms which was previously difficult through traditional microbiological methods. Additionally, rapid detection by molecular methods is now possible for pathogens of public health importance. And can therefore contribute to provide public health information such as strain characterization by genotyping.
Further, the report states that one of the major factors hindering the growth of this market is lack of efficiency and effectiveness compared to conventional methods. Although molecular diagnostics has several advantages, it cannot yet replace conventional diagnostic methods for a range of infectious diseases since many of the tests used in clinical microbiology are efficient and inexpensive. Advances in conventional technologies have further resulted in many rapid antigen tests requiring lesser time and modern automated culture systems allow rapid identification and susceptibility testing. All PCR techniques except broad-range PCR can only detect DNA of an organism which is complementary to primers used. Therefore, to address this issue, inexpensive and simple microarray technologies would be required however, they are not yet available.
Bio-Rad, GE Healthcare, Thermo Fisher Scientific, Analytik Jena, Cleaver Scientific, Corning, eikonix, Gel Company, Syngene, TBG Diagnostics, and VWR International.